Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic strategy for managing metabolic syndromes. These naturally occurring substances are secreted by the gut in response to meal intake, stimulating insulin production and suppressing glucagon output. GLP-1 derivatives demonstrate promising therapeutic results in treating t